05:16 PM EDT, 03/25/2025 (MT Newswires) -- Veracyte ( VCYT ) late Tuesday said new data from a clinical trial showed its whole-genome sequencing-based platform detected cancer recurrence in patients treated for muscle-invasive bladder cancer with greater accuracy than droplet digital PCR-based blood testing and earlier than standard imaging.

The company presented the findings at the annual European Association of Urology Congress in Madrid, Spain.

The study enrolled 100 patients undergoing neoadjuvant chemotherapy and radical cystectomy. According to the company, the whole-genome sequencing platform had a negative predictive value of 95.9% compared to 96.2% for blood testing after six months, while demonstrating an 88% specificity rate compared to 62% for patients tested with the blood-based method.

The platform also detected cancer recurrence a median of 93 days earlier than imaging, the company added.

Veracyte ( VCYT ) plans to launch its first minimal residual disease test for muscle-invasive bladder cancer in the first half of 2026.